Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
200 shown of 8,491 total abstracts
  1. Abstract 14062026-04-05 · 13:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-421 study)
    M.C. Garassino, M. Krop · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 11132026-04-01 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-263
    H. Rugo, S. Peters, M. Reck, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 12512026-04-01 · 16:00 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    G. Curigliano, S. Tolaney, C. Saura, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 92592026-04-05 · 21:00 CT · Hall B1
    Long-term follow-up of Keytruda neoadjuvant for SCLC: KEYNOTE-994
    M.C. Garassino, F. Andre, P. Schmid, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  5. Abstract 12052026-04-05 · 19:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-923
    R. Herbst, T. Mok, H. Borghaei, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 14802026-04-04 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-984 study)
    J. Brahmer, C. Saura · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 99572026-04-02 · 14:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-776 study)
    M.C. Garassino, H. Borghaei, F. Andre, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 17132026-04-05 · 21:15 CT · S100A
    IMpower-957: Tecentriq (atezolizumab) 1L in TNBC
    E. Winer, S. Antonia, L. Paz-Ares · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 98582026-04-03 · 15:00 CT · S100A
    Quality of life outcomes with Keytruda in patients with NSCLC
    M. Reck, J. Cortes, R. Herbst, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 10992026-04-03 · 19:30 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    J. Cortes, C. Saura, M. Reck, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 42602026-04-02 · 16:30 CT · S406
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-154
    L. Paz-Ares, S. Tolaney, J. Brahmer, et al. · Mayo Clinic
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  12. Abstract 10872026-04-01 · 20:30 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    G. Curigliano, C. Saura, J. Brahmer, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 44002026-04-04 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for HCC: CheckMate-96
    E. Winer, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  14. Abstract 41462026-04-04 · 16:45 CT · S100A
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-348
    F. Andre, R. Herbst, T. Mok · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  15. Abstract 11842026-04-02 · 19:00 CT · S100A
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-356
    J. Cortes, S. Peters, M. Krop · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 49732026-04-02 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 2L for biliary tract: PACIFIC-885
    A. Spira, G. Curigliano · Karolinska Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  17. Abstract 11252026-04-05 · 14:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-80 study)
    M. Krop, L. Paz-Ares, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 93932026-04-05 · 15:00 CT · E450
    DESTINY-Breast-582: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    S. Antonia, S. Peters, J. Brahmer, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 95272026-04-05 · 13:30 CT · Hall B1
    FLAURA-29: Tagrisso (osimertinib) adjuvant in NSCLC
    S. Peters, M. Krop, E. Winer · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 64442026-04-05 · 13:15 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-913
    G. Curigliano, C. Saura, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 19972026-04-01 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-111 study)
    P. Schmid, E. Winer, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 12642026-04-01 · 18:45 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-39
    L. Paz-Ares, S. Tolaney · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 94842026-04-01 · 14:15 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    S. Antonia, S. Tolaney · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  24. Abstract 11872026-04-01 · 13:15 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-345
    G. Curigliano, M. Reck, N. Rizvi, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 14252026-04-03 · 16:45 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-900
    N. Rizvi, H. Rugo, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 49742026-04-01 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-719 study)
    H. Rugo, S. Antonia · National Cancer Center Japan
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  27. Abstract 56502026-04-01 · 20:00 CT · E450
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-667
    S. Tolaney, M. Reck, H. Borghaei, et al. · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  28. Abstract 18442026-04-05 · 16:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-534 study)
    S. Tolaney, H. Rugo, M. Krop · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 45332026-04-05 · 19:00 CT · S406
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    H. Borghaei, F. Andre, T. Mok, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  30. Abstract 18082026-04-03 · 16:00 CT · S406
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    C. Saura, L. Paz-Ares, H. Rugo · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 11882026-04-03 · 21:00 CT · S406
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-488
    E. Winer, J. Brahmer, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 99552026-04-03 · 21:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-241
    H. Borghaei, P. Schmid, S. Antonia · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 15012026-04-03 · 19:15 CT · E450
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    P. Schmid, M.C. Garassino, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 55342026-04-04 · 13:30 CT · S406
    Long-term follow-up of Lynparza 3L+ for prostate: OlympiA-219
    N. Rizvi, T. Mok, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  35. Abstract 99212026-04-03 · 20:15 CT · Hall B1
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-942
    G. Curigliano, P. Schmid, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 19492026-04-05 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-184 study)
    A. Spira, T. Mok, H. Borghaei · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 46422026-04-05 · 16:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-755 study)
    L. Paz-Ares, C. Robert, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  38. Abstract 41402026-04-01 · 18:15 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    J. Brahmer, J. Cortes, A. Spira, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  39. Abstract 42432026-04-02 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-133
    S. Antonia, J. Brahmer, L. Paz-Ares · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  40. Abstract 14332026-04-02 · 16:45 CT · Hall B1
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-304
    C. Saura, J. Cortes, H. Borghaei · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 99552026-04-05 · 20:00 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-871
    J. Cortes, M.C. Garassino, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  42. Abstract 19142026-04-01 · 21:00 CT · S406
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-573
    J. Cortes, M. Reck, G. Curigliano, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 101212026-04-04 · 16:45 CT · Arie Crown Theater
    KEYNOTE-921: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    M. Krop, A. Spira, F. Andre, et al. · Royal Marsden Hospital
    Poster Discussion SessionMelanoma📄🖼️
  44. Abstract 16362026-04-02 · 16:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-452
    S. Modi, N. Rizvi, F. Andre, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 45272026-04-01 · 21:30 CT · S100A
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-859 study)
    S. Modi, S. Peters, M. Krop, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  46. Abstract 19042026-04-02 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-233 study)
    H. Rugo, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 16242026-04-03 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-870 study)
    M.C. Garassino, J. Cortes, J. Brahmer · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 95542026-04-04 · 20:45 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    J. Brahmer, R. Herbst · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  49. Abstract 90852026-04-05 · 19:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-846
    A. Spira, P. Schmid, G. Curigliano, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 97692026-04-04 · 21:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-366
    R. Herbst, L. Paz-Ares · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract 12342026-04-05 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-860
    M. Krop, E. Winer, S. Tolaney, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 49752026-04-02 · 18:30 CT · S406
    Long-term follow-up of Tecentriq 1L for HCC: IMpower-692
    M.C. Garassino, C. Saura, G. Curigliano, et al. · Cleveland Clinic
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  53. Abstract 12682026-04-05 · 18:15 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    J. Brahmer, P. Schmid, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 92782026-04-05 · 19:45 CT · E450
    Quality of life outcomes with Keytruda in patients with SCLC
    H. Rugo, S. Antonia, F. Andre, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  55. Abstract 55232026-04-04 · 14:00 CT · E450
    Quality of life outcomes with Lynparza in patients with prostate
    A. Spira, R. Herbst, S. Modi, et al. · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  56. Abstract 13672026-04-03 · 20:45 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M. Krop, J. Cortes, S. Antonia · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 61662026-04-01 · 16:45 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    L. Paz-Ares, H. Rugo, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGynecologic Cancer📄🖼️
  58. Abstract 98212026-04-05 · 19:45 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-346
    M. Reck, H. Rugo, P. Schmid · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  59. Abstract 16792026-04-05 · 20:00 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-47
    R. Herbst, S. Tolaney, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 16392026-04-05 · 18:00 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-203
    A. Spira, G. Curigliano, M. Reck, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 14862026-04-02 · 19:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-337 study)
    G. Curigliano, C. Robert, S. Antonia, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 57252026-04-04 · 16:00 CT · S406
    Long-term follow-up of Lynparza 2L for prostate: OlympiA-329
    P. Schmid, S. Modi, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  63. Abstract 44112026-04-05 · 18:30 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-453
    P. Schmid, T. Mok, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  64. Abstract 99542026-04-05 · 19:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-234
    E. Winer, S. Peters, H. Borghaei, et al. · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  65. Abstract 17312026-04-01 · 15:30 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    H. Rugo, E. Winer · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 92752026-04-01 · 21:45 CT · S100A
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-666
    E. Winer, C. Saura, H. Borghaei · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 90972026-04-05 · 19:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-907
    L. Paz-Ares, S. Tolaney, S. Peters, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 93582026-04-05 · 18:30 CT · S406
    FLAURA-617: Tagrisso (osimertinib) adjuvant in NSCLC
    L. Paz-Ares, H. Borghaei · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  69. Abstract 19292026-04-01 · 18:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-982
    R. Herbst, M. Reck, P. Schmid · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 48852026-04-03 · 13:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-159
    S. Modi, M. Krop, H. Rugo, et al. · University of Chicago
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  71. Abstract 61862026-04-02 · 15:45 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-457
    G. Curigliano, C. Saura, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  72. Abstract 99152026-04-01 · 21:30 CT · Arie Crown Theater
    DESTINY-Breast-41: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    T. Mok, H. Rugo, R. Herbst · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 49902026-04-03 · 21:15 CT · S406
    EV-227: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    F. Andre, C. Saura, R. Herbst · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  74. Abstract 16242026-04-05 · 16:45 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-548
    S. Peters, N. Rizvi · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 15062026-04-03 · 13:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-987
    J. Cortes, H. Rugo, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 91282026-04-01 · 21:00 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    A. Spira, S. Modi, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 48342026-04-04 · 20:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-763
    S. Antonia, L. Paz-Ares, G. Curigliano · University of Chicago
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  78. Abstract 92782026-04-02 · 16:00 CT · S100A
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-630
    M. Reck, R. Herbst, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract 18362026-04-05 · 15:30 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    L. Paz-Ares, M.C. Garassino, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 18292026-04-03 · 18:00 CT · S100A
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-726
    P. Schmid, E. Winer · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 94692026-04-03 · 19:45 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-727
    S. Tolaney, S. Antonia, N. Rizvi, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  82. Abstract 92692026-04-03 · 18:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    H. Borghaei, S. Peters, C. Robert · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  83. Abstract 13212026-04-03 · 19:15 CT · E450
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    L. Paz-Ares, F. Andre, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 10812026-04-02 · 16:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-552
    J. Brahmer, C. Saura, J. Cortes, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 44552026-04-03 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-684
    S. Tolaney, S. Peters, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  86. Abstract 63042026-04-05 · 13:15 CT · S100A
    Quality of life outcomes with Opdivo in patients with RCC
    P. Schmid, M. Krop, C. Robert · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  87. Abstract 17422026-04-04 · 21:15 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-568
    T. Mok, N. Rizvi, S. Peters, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 14052026-04-03 · 15:45 CT · S100A
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-109
    M. Krop, C. Saura · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 45092026-04-04 · 20:15 CT · S100A
    ASCENT-477: Trodelvy (sacituzumab govitecan) adjuvant in urothelial carcinoma
    S. Tolaney, C. Robert, L. Paz-Ares, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  90. Abstract 13862026-04-01 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-402
    H. Rugo, S. Modi, M. Krop · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 10692026-04-05 · 18:45 CT · Arie Crown Theater
    MONALEESA-312: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    L. Paz-Ares, M.C. Garassino, C. Robert · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 94232026-04-01 · 13:00 CT · S100A
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-93
    C. Saura, C. Robert, S. Tolaney · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  93. Abstract 93222026-04-01 · 15:00 CT · Hall B1
    PACIFIC-869: Imfinzi (durvalumab) 1L in SCLC
    C. Saura, S. Tolaney, P. Schmid, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  94. Abstract 90252026-04-02 · 16:00 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for SCLC: KEYNOTE-43
    S. Modi, G. Curigliano, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  95. Abstract 93812026-04-04 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-574 study)
    F. Andre, C. Saura, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 16092026-04-01 · 21:00 CT · Arie Crown Theater
    DESTINY-Breast-421: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    M.C. Garassino, M. Krop, S. Antonia, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 68242026-04-02 · 21:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-917
    S. Tolaney, R. Herbst, M. Krop · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  98. Abstract 61462026-04-03 · 21:30 CT · E450
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-216
    J. Cortes, L. Paz-Ares, R. Herbst, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  99. Abstract 42952026-04-02 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-493 study)
    S. Antonia, C. Saura, C. Robert, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  100. Abstract 12072026-04-01 · 18:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-266
    C. Robert, H. Borghaei, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 92782026-04-04 · 20:00 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with NSCLC
    H. Rugo, C. Saura, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  102. Abstract 40782026-04-05 · 21:30 CT · E450
    CheckMate-886: Opdivo (nivolumab) maintenance in HCC
    T. Mok, N. Rizvi, H. Borghaei, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  103. Abstract 17362026-04-02 · 13:00 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-276 study)
    M. Reck, J. Cortes, G. Curigliano, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 62562026-04-02 · 21:30 CT · E450
    OlympiA-226: Lynparza (olaparib) 3L+ in ovarian
    H. Rugo, C. Robert, S. Modi, et al. · Karolinska Institute
    Poster Discussion SessionGynecologic Cancer📄🖼️
  105. Abstract 17632026-04-03 · 21:30 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    M. Krop, E. Winer, L. Paz-Ares, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 11692026-04-03 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-280 study)
    M. Krop, S. Antonia, E. Winer, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 10822026-04-03 · 13:15 CT · Arie Crown Theater
    MONALEESA-969: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    C. Robert, S. Peters, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 18492026-04-05 · 14:45 CT · S100A
    Long-term follow-up of Keytruda maintenance for TNBC: KEYNOTE-216
    A. Spira, H. Borghaei, M. Krop, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 12352026-04-03 · 16:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-178
    E. Winer, L. Paz-Ares, H. Borghaei · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 10852026-04-04 · 13:00 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-449 study)
    T. Mok, H. Borghaei · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 43612026-04-02 · 20:15 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with HCC
    S. Modi, E. Winer, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  112. Abstract 19412026-04-02 · 14:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-747
    R. Herbst, G. Curigliano, H. Borghaei, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 45762026-04-05 · 14:15 CT · E450
    Quality of life outcomes with Imfinzi in patients with biliary tract
    C. Saura, S. Tolaney · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  114. Abstract 18092026-04-01 · 20:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-64 study)
    S. Peters, L. Paz-Ares · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 98722026-04-02 · 21:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-756
    J. Brahmer, L. Paz-Ares · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 12742026-04-05 · 20:30 CT · Arie Crown Theater
    IMpower-396: Tecentriq (atezolizumab) 3L+ in TNBC
    T. Mok, F. Andre, N. Rizvi, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 11632026-04-05 · 16:00 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    N. Rizvi, H. Rugo, C. Robert · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 46342026-04-03 · 20:00 CT · S100A
    EV-645: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    H. Borghaei, M. Krop, J. Cortes, et al. · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  119. Abstract 43002026-04-01 · 15:00 CT · S406
    EV-931: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    N. Rizvi, A. Spira · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  120. Abstract 98182026-04-05 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-309 study)
    R. Herbst, M. Reck · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  121. Abstract 95962026-04-05 · 14:45 CT · E450
    KEYNOTE-211: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    S. Antonia, H. Borghaei, M. Reck · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  122. Abstract 47772026-04-05 · 15:15 CT · S406
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-662
    R. Herbst, M. Reck, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  123. Abstract 43632026-04-03 · 18:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-108 study)
    S. Peters, C. Saura, C. Robert · MD Anderson Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  124. Abstract 98702026-04-02 · 19:30 CT · Arie Crown Theater
    FLAURA-164: Tagrisso (osimertinib) 2L in NSCLC
    C. Robert, N. Rizvi, C. Saura · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 94902026-04-01 · 18:45 CT · S100A
    FLAURA-380: Tagrisso (osimertinib) 3L+ in NSCLC
    A. Spira, H. Rugo, F. Andre, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  126. Abstract 64662026-04-02 · 21:00 CT · Hall B1
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-568
    L. Paz-Ares, H. Borghaei · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  127. Abstract 46502026-04-04 · 20:45 CT · E450
    PACIFIC-990: Imfinzi (durvalumab) neoadjuvant in biliary tract
    G. Curigliano, C. Saura, C. Robert, et al. · Karolinska Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  128. Abstract 46092026-04-02 · 15:30 CT · S406
    EV-977: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    C. Robert, R. Herbst · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  129. Abstract 47282026-04-05 · 21:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with HCC
    G. Curigliano, L. Paz-Ares · Chinese University of Hong Kong
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  130. Abstract 14082026-04-03 · 14:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-373
    J. Cortes, M. Krop, S. Modi · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 42062026-04-03 · 20:45 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-677 study)
    J. Cortes, C. Robert, S. Tolaney · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  132. Abstract 68112026-04-01 · 21:00 CT · Hall B1
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-928
    M. Reck, H. Borghaei, H. Rugo, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  133. Abstract 46172026-04-02 · 13:30 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in gastric
    S. Tolaney, M.C. Garassino · National Cancer Center Japan
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  134. Abstract 10972026-04-04 · 16:15 CT · S406
    MONARCH-213: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    C. Robert, A. Spira, C. Saura, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 11062026-04-05 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-206 study)
    N. Rizvi, J. Brahmer, M. Reck, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 64572026-04-04 · 18:00 CT · Hall B1
    CheckMate-709: Opdivo (nivolumab) neoadjuvant in RCC
    C. Saura, H. Borghaei, F. Andre · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  137. Abstract 63952026-04-02 · 21:45 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-982
    E. Winer, S. Tolaney, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  138. Abstract 11392026-04-04 · 13:00 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    M.C. Garassino, M. Krop, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 41212026-04-03 · 13:00 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    J. Cortes, P. Schmid, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  140. Abstract 14292026-04-04 · 21:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-679
    G. Curigliano, L. Paz-Ares, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 43402026-04-04 · 19:45 CT · E450
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-452 study)
    J. Cortes, C. Robert, R. Herbst, et al. · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  142. Abstract 17612026-04-02 · 14:45 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-72
    F. Andre, S. Tolaney, C. Saura, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 97612026-04-02 · 18:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-401
    S. Antonia, L. Paz-Ares, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  144. Abstract 46852026-04-01 · 19:30 CT · S100A
    Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-380
    M. Reck, E. Winer, N. Rizvi, et al. · Mayo Clinic
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  145. Abstract 92942026-04-05 · 16:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-918 study)
    N. Rizvi, H. Borghaei, S. Antonia, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  146. Abstract 45312026-04-04 · 19:30 CT · S100A
    EV-934: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    J. Brahmer, M. Reck, A. Spira, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  147. Abstract 96792026-04-03 · 18:15 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-835
    H. Rugo, S. Peters, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  148. Abstract 90152026-04-02 · 14:30 CT · E450
    FLAURA-889: Tagrisso (osimertinib) 1L in NSCLC
    C. Saura, G. Curigliano · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  149. Abstract 19132026-04-01 · 20:30 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-82 study)
    M. Krop, J. Cortes · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 42592026-04-04 · 18:15 CT · E450
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-986
    S. Tolaney, A. Spira, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  151. Abstract 49212026-04-03 · 13:15 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-553
    F. Andre, M. Reck, M.C. Garassino · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  152. Abstract 16962026-04-04 · 16:45 CT · S406
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-359
    R. Herbst, T. Mok · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 67172026-04-02 · 16:15 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in RCC
    N. Rizvi, F. Andre · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  154. Abstract 93752026-04-02 · 16:45 CT · Arie Crown Theater
    FLAURA-415: Tagrisso (osimertinib) maintenance in NSCLC
    C. Robert, S. Antonia, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  155. Abstract 91412026-04-05 · 16:15 CT · E450
    DESTINY-Breast-278: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    L. Paz-Ares, C. Saura, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  156. Abstract 91322026-04-04 · 13:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-886
    R. Herbst, G. Curigliano · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  157. Abstract 46652026-04-01 · 15:00 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-634 study)
    R. Herbst, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  158. Abstract 15032026-04-05 · 20:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-657 study)
    T. Mok, H. Borghaei · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 67182026-04-05 · 13:45 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-515 study)
    C. Saura, N. Rizvi, P. Schmid · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  160. Abstract 16252026-04-05 · 14:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-324
    C. Saura, E. Winer · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 41022026-04-03 · 20:30 CT · Hall B1
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-315
    A. Spira, C. Robert · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  162. Abstract 46472026-04-02 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-779
    A. Spira, J. Brahmer, N. Rizvi · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  163. Abstract 17882026-04-03 · 16:15 CT · E450
    MONARCH-244: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    R. Herbst, M. Krop, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 18802026-04-04 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-143 study)
    S. Peters, F. Andre, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 19612026-04-05 · 18:30 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-452
    M.C. Garassino, S. Peters · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 19192026-04-03 · 20:00 CT · S100A
    MONALEESA-830: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    H. Borghaei, P. Schmid · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 98402026-04-03 · 13:15 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    N. Rizvi, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  168. Abstract 48572026-04-05 · 14:15 CT · S406
    IMpower-832: Tecentriq (atezolizumab) 2L in HCC
    P. Schmid, C. Robert, R. Herbst · Karolinska Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  169. Abstract 41492026-04-04 · 13:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-244 study)
    P. Schmid, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  170. Abstract 18172026-04-04 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-348 study)
    J. Brahmer, S. Peters, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 11662026-04-04 · 21:00 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-56
    N. Rizvi, S. Peters, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 45072026-04-04 · 16:15 CT · S406
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-935 study)
    J. Brahmer, M. Krop · Peter MacCallum Cancer Centre
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  173. Abstract 19262026-04-05 · 19:45 CT · S406
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-351
    L. Paz-Ares, F. Andre, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 96972026-04-05 · 13:45 CT · Arie Crown Theater
    PACIFIC-820: Imfinzi (durvalumab) maintenance in NSCLC
    N. Rizvi, L. Paz-Ares · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  175. Abstract 11012026-04-01 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-750 study)
    C. Robert, M. Reck, L. Paz-Ares, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 14952026-04-01 · 19:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-215 study)
    H. Borghaei, J. Brahmer · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 18372026-04-03 · 20:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-782
    S. Peters, G. Curigliano, M. Reck · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 90552026-04-03 · 20:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-51
    J. Cortes, J. Brahmer, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  179. Abstract 18312026-04-02 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-697 study)
    E. Winer, F. Andre, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 43462026-04-05 · 16:15 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-94
    L. Paz-Ares, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  181. Abstract 49362026-04-03 · 13:30 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    E. Winer, M. Krop · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  182. Abstract 49292026-04-05 · 16:30 CT · S406
    Quality of life outcomes with Enhertu in patients with gastric
    P. Schmid, R. Herbst, J. Cortes · Karolinska Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  183. Abstract 60872026-04-02 · 18:00 CT · Hall B1
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-163
    S. Peters, C. Saura, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  184. Abstract 49612026-04-04 · 21:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-500
    S. Modi, C. Saura, P. Schmid, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  185. Abstract 42092026-04-01 · 20:30 CT · Hall B1
    EV-718: Padcev (enfortumab vedotin) maintenance in urothelial carcinoma
    R. Herbst, M. Reck, F. Andre, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  186. Abstract 16752026-04-05 · 19:00 CT · E450
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-540
    M.C. Garassino, S. Peters, G. Curigliano · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 18532026-04-01 · 16:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-826 study)
    L. Paz-Ares, R. Herbst, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 19292026-04-05 · 13:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-429 study)
    E. Winer, J. Cortes · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 12632026-04-01 · 14:30 CT · Hall B1
    OlympiA-899: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    A. Spira, E. Winer, H. Rugo, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 95952026-04-01 · 19:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    C. Saura, S. Modi · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  191. Abstract 95762026-04-02 · 20:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-807 study)
    S. Modi, H. Rugo, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  192. Abstract 15202026-04-03 · 16:30 CT · E450
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-83
    F. Andre, L. Paz-Ares, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 101092026-04-05 · 14:45 CT · Hall B1
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-892
    S. Modi, M. Krop, R. Herbst, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  194. Abstract 96312026-04-04 · 14:45 CT · S100A
    Quality of life outcomes with Imfinzi in patients with NSCLC
    P. Schmid, S. Antonia, G. Curigliano · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  195. Abstract 13932026-04-04 · 13:45 CT · E450
    MONARCH-731: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    F. Andre, H. Borghaei, S. Peters · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 16192026-04-01 · 18:00 CT · Hall B1
    KEYNOTE-20: Keytruda (pembrolizumab) adjuvant in TNBC
    S. Peters, C. Robert, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 61782026-04-01 · 20:45 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-613 study)
    S. Tolaney, H. Borghaei, J. Cortes · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  198. Abstract 11202026-04-02 · 20:00 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-413 study)
    S. Modi, R. Herbst, A. Spira, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 47982026-04-02 · 16:00 CT · S406
    Opdivo plus chemotherapy in previously untreated HCC: updated analysis from CheckMate-484
    F. Andre, A. Spira, C. Saura, et al. · Massachusetts General Hospital
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  200. Abstract 14032026-04-05 · 13:00 CT · S406
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-316
    C. Robert, R. Herbst, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.